RE: Just ask yourself...28 Sep 2025 11:00
The post by H4H yesterday sums it all up in a nutshell the big boys understand the data and know it's working this is going to be big. FDA knows it works, MD Anderson knows it works, Estonia knows it works, and now big investors who know it works are investing. Don't be fooled into selling your valuable shares, they will be worth so much more very soon. This is why I'm buying more & more I don't sell I just buy building a big holding for the big day...
Posted by H4H yesterday
Why do you think Carl June of the University of Pennsylvania and his team, the world leaders of CAR-T therapy would choose to assist Hemogenyx in bringing HG-CT-1 to the clinic?
Why do you think Prevail would invest in Hemogenyx at a premium that was hundreds of percent above the current share price?
Why would MD Anderson, arguably the leading cancer hospital in the world want to run the first trial of HG-CT-1?
Why would Made Scientific who specialise in large scale commercial roll-out of CAR-T therapy want to partner Hemogenyx?
Why would Cellin Technologies want to do the same to treat patients in Estonia, the EU and ultimately worldwide?
Why would the FDA give Hemogenyx approval to treat pediatric patients after seeing data from just two patients?
And why are all three patients from the first cohort treated with HG-CT-1 still alive when all other treatment options had been tried and had failed?
Here's what I think. With three patients treated, who literally had weeks to live, being alive after one month, five months and seven months respectively, at least one with zero sign of any cancer, we are witnessing a paradigm shift in the treatment of r/r AML. I believe HG-CT-1 will cure some patients whilst treating others, extending their lives for many months if not years.
I also believe HG-CT-1 is extremely valuable in financial terms, both to the company and also to investors. It is just a matter of time before a major becomes involved, either through licencing, a buy out of the product candidate or most likely the company. Investors should be mindful that Hemogenyx also have their CDX bi-specific antibody which is more valuable than HG-CT-1 and CBR, which is potentially more valuable than both of them combined. When Vlad talks about billions and years (and we're had the years) he is very serious.
So as an individual I'll watch the traders, the games the market makers play, the fear and panic they create. They can shake the tree with a hurricane force if they desire, I'm not going to budge. I haven't just got sticky fingers. I'm glued to it!
Brilliant post👍
Sign In
Follow the stocks
